Skip to content

Ammoxetine hydrochloride enteric-coated tablets

DRUG7 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

DepressionHealthy ParticipantsMajor Depressive Disorder (MDD)Participants With Mild Hepatic ImpairmentParticipants With Moderate Hepatic ImpairmentParticipants With Moderate Renal Impairment

Phase 1

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects
CompletedNCT03456388
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Depression
Start: 2017-10-30End: 2019-02-15Updated: 2019-02-20
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject
NCT03850834
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Depression
Start: 2019-03-10End: 2019-10-31Target: 36Updated: 2019-02-22
Food-effect Study of Ammoxetine Hydrochloride Enteric-coated Tablets
CompletedNCT07508501
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy Participants
Start: 2023-02-08End: 2023-04-04Updated: 2026-04-02
A Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects
CompletedNCT07508462
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy Participants
Start: 2024-05-30End: 2024-08-02Updated: 2026-04-02
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function
RecruitingNCT07694843
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy Participants, Participants With Mild Hepatic Impairment, Participants With Moderate Hepatic Impairment
Start: 2026-03-30End: 2026-11-30Target: 24Updated: 2026-07-10
A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
RecruitingNCT07694869
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy Participants, Participants With Moderate Renal Impairment
Start: 2026-05-10End: 2026-11-11Target: 16Updated: 2026-07-10

Phase 2